scholarly journals Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide with Busulfan, Fludarabine and Thiotepa Conditioning for Children with Thalassemia Major

2020 ◽  
Vol 26 (3) ◽  
pp. S218-S219
Author(s):  
Satya Prakash Yadav ◽  
Anil Sharma ◽  
Rohit Kapoor ◽  
Goutomi Chatterjee ◽  
Neha Rastogi
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplant ◽  
Thalassemia Major ◽  
Cell Transplant ◽  
Post Transplant

Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide in Pediatric Hemophagocytic Lymphohistiocytosis

2021 ◽  
Author(s):  
Diego Medina-Valencia ◽  
Daniela Cleves ◽  
Estefania Beltran ◽  
Natalia Builes ◽  
Alexis A. Franco ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Post Transplant

scholarly journals A Novel Secondary Neoplasm Following Allogeneic Hematopoietic Stem Cell Transplant: Mixed Donor-Recipient Primitive Mesenchymal Proliferation of the Liver

2021 ◽  
pp. 109352662110016
Author(s):  
Brian Earl ◽  
Zi Fan Yang ◽  
Harini Rao ◽  
Grace Cheng ◽  
Donna Wall ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Graft Versus Host Disease ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host ◽  
Post Transplant

Post-hematopoietic stem cell transplant secondary solid neoplasms are uncommon and usually host-derived. We describe a 6-year-old female who developed a mixed donor-recipient origin mesenchymal stromal tumor-like lesion in the liver following an unrelated hematopoietic stem cell transplant complicated by severe graft-versus-host disease. This lesion arose early post-transplant in association with hepatic graft-versus-host disease. At 12 years post-transplant, the neoplasm has progressively shrunken in size and the patient remains well with no neoplasm-associated sequelae. This report characterizes a novel lesion of mixed origin post-transplant and offers unique insights into the contribution of bone marrow-derived cells to extra-medullary tissues.

037 Post-transplant lymphoproliferative disorder in skeletal muscle arising seven years after allogeneic stem cell transplant

2018 ◽  
Vol 89 (6) ◽  
pp. A15.3-A16
Author(s):  
Alice Powell ◽  
Joanne Sy ◽  
Yael Barnett ◽  
Simon Mosalski ◽  
Bruce Brew ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Stem Cell ◽  
Lymphoproliferative Disorder ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Percutaneous Endoscopic Gastrostomy Tube ◽  
Allogeneic Stem Cell Transplant ◽  
Intravenous Immunoglobulin Therapy ◽  
Post Transplant ◽  
Proximal Myopathy

IntroductionPost-transplant lymphoproliferative disorder (PTLD) is a well-recognised serious complication of transplantation. However, it rarely affects muscle.MethodsA case report detailing presentation, evaluation, management and outcome of a patient with acute on chronic proximal myopathy on a background of allogeneic stem cell transplant is described. The patient was diagnosed with PTLD affecting skeletal muscle.ResultsA 54 year old man presented with painful proximal myopathy seven years after successful allogeneic stem cell transplant for acute myeloid leukaemia. He had been managed with immunosuppression for extensive cutaneous graft versus host disease (GVHD) from the time of transplant. Initial quadriceps muscle biopsy showed changes in keeping with GVHD and features suggestive of drug-related necrotising myositis. The painful myalgia evolved to include bulbar muscles with dysphagia despite pulse steroid and intravenous immunoglobulin therapy. A positron emission tomography (PET) scan demonstrated intense and extensive hyper-metabolism in multiple muscle groups in keeping with diffuse myositis with the most prominent activity involving neck muscles, the left shoulder girdle and left arm musculature. A second biopsy of the sternocleidomastoid demonstrated infiltration with haematolymphoid cells consistent with post-transplant lymphoproliferative disorder. Treatment with reduction in immunosuppression, rituximab and rehabilitation saw improvement in myalgia and weakness. Unfortunately, exacerbation of chronic GVHD ensued following reduction in immunosuppression and contributed to oesophageal stricturing eventually requiring a percutaneous endoscopic gastrostomy tube for feeding.ConclusionThis case highlights the complex morbidity of allogeneic stem cell transplant and the need to consider PTLD in the differential for patients who present with neurological symptoms.

Sign in / Sign up

Export Citation Format

Share Document